Dianthus Therapeutics (DNTH) to Release Earnings on Monday

Key Points

• Q1 2026 results: Dianthus will report after the close on Monday, May 11 (conference call May 13 at 4:00 PM ET); analysts forecast EPS of ($1.1029) and revenue of $0.404M, and expect roughly -$4 EPS for the current fiscal year and -$5 next year.
• Shares rose 3.6% to $90.58 (market cap ~$4.93B) and several firms have raised targets—HC Wainwright to $130 and Oppenheimer to $145—leaving a consensus Buy rating with an average price target of $115.55.
• Insiders sold 323,021 shares (~$26.6M) over the last 90 days (insiders own 3.02%), while institutions hold about 47.5% of the stock; the company is a clinical‑stage biotech developing DNTH103, currently in Phase 2 trials.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) is expected to be releasing its Q1 2026 results after the market closes on Monday, May 11th. Analysts expect Dianthus Therapeutics to post earnings of ($1.1029) per share and revenue of $0.4040 million for the quarter. Investors may visit the the company's upcoming Q1 2026 earning results page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 4:00 PM ET.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last posted its quarterly earnings results on Monday, March 9th. The company reported ($1.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.46). The company had revenue of $0.57 million during the quarter, compared to analyst estimates of $0.40 million. Dianthus Therapeutics had a negative net margin of 7,973.33% and a negative return on equity of 38.85%. On average, analysts expect Dianthus Therapeutics to post $-4 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Dianthus Therapeutics Stock Up 3.6%

Shares of NASDAQ:DNTH traded up $3.16 on Monday, reaching $90.58. 56,739 shares of the company's stock were exchanged, compared to its average volume of 945,694. The firm has a market capitalization of $4.93 billion, a price-to-earnings ratio of -22.09 and a beta of 1.18. Dianthus Therapeutics has a fifty-two week low of $16.64 and a fifty-two week high of $96.50. The business's 50-day moving average is $78.79 and its two-hundred day moving average is $55.19.

Analyst Ratings Changes

Several research firms have recently commented on DNTH. HC Wainwright upped their price target on shares of Dianthus Therapeutics from $47.00 to $130.00 and gave the stock a "buy" rating in a research report on Monday, March 9th. Oppenheimer upped their price objective on shares of Dianthus Therapeutics to $145.00 and gave the stock an "outperform" rating in a report on Monday, March 9th. TD Cowen reissued a "buy" rating on shares of Dianthus Therapeutics in a research note on Monday, March 9th. Wells Fargo & Company assumed coverage on shares of Dianthus Therapeutics in a research note on Thursday, March 19th. They set an "overweight" rating and a $135.00 target price on the stock. Finally, Jefferies Financial Group set a $98.00 target price on shares of Dianthus Therapeutics and gave the company a "buy" rating in a research note on Monday, March 9th. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Dianthus Therapeutics has a consensus rating of "Buy" and an average price target of $115.55.

Insider Buying and Selling at Dianthus Therapeutics

In other Dianthus Therapeutics news, EVP Ryan Savitz sold 114,367 shares of the firm's stock in a transaction dated Tuesday, March 31st. The shares were sold at an average price of $83.00, for a total value of $9,492,461.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Edward Carr sold 43,682 shares of the firm's stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $81.49, for a total transaction of $3,559,646.18. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 323,021 shares of company stock worth $26,564,008. 3.02% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Sei Investments Co. acquired a new stake in shares of Dianthus Therapeutics during the third quarter worth approximately $562,000. MetLife Investment Management LLC boosted its holdings in shares of Dianthus Therapeutics by 41.0% during the fourth quarter. MetLife Investment Management LLC now owns 13,555 shares of the company's stock worth $559,000 after purchasing an additional 3,942 shares during the period. Rafferty Asset Management LLC boosted its holdings in shares of Dianthus Therapeutics by 19.5% during the second quarter. Rafferty Asset Management LLC now owns 28,522 shares of the company's stock worth $531,000 after purchasing an additional 4,650 shares during the period. Persistent Asset Partners Ltd acquired a new stake in shares of Dianthus Therapeutics during the fourth quarter worth approximately $401,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Dianthus Therapeutics by 4.2% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company's stock worth $280,000 after purchasing an additional 618 shares during the period. 47.53% of the stock is currently owned by institutional investors and hedge funds.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.